NCT04238702View on ClinicalTrials.gov

Renohemodynamic Effects of Combined empagliflOzin and LosARtan

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

September 27, 2021

Study Completion Date

September 27, 2021

Conditions
Diabetes Mellitus, Type 2Diabetic Kidney Disease
Interventions
DRUG

Empagliflozin 10 MG

Empagliflozin 10 MG 7 days intervention period

DRUG

Losartan 50Mg Tab

Losartan 50 MG 7 days intervention period

OTHER

Placebo

Placebo 7 days intervention period

Trial Locations (1)

1081HV

VU University Medical Center, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER

NCT04238702 - Renohemodynamic Effects of Combined empagliflOzin and LosARtan | Biotech Hunter | Biotech Hunter